AnPac Bio-Medical Science Co

Anpac Bio-Medical Science Co., Ltd., is a biotechnology company. It engages in marketing and selling multi-cancer screening and detection test that uses patented cancer differentiation analysis, or CDA, technology and proprietary cancer-detection device or CDA device. The company was founded by Chris Chang Yu and He Yu in 2010 and is headquartered in Lishui, China.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Fresh2 Group Ltd. is a biotechnology company. It engages in marketing and selling multi-cancer screening and detection test that uses patented cancer differentiation analysis, or CDA, technology and proprietary cancer-detection device or CDA device. The company was founded by Chris Chang Yu and He Yu in January 2010 and is headquartered in Lishui, China.

Ticker symbol change effective at the market open May 22, 2023 NEW YORK , May 19, 2023 /PRNewswire/ -- Fresh2 Group Ltd., formerly AnPac Bio-Medical Science Co., Ltd.

Fresh2 Group Ltd. Announces Nasdaq Ticker Symbol Change from 'ANPC' to 'FRES'

NEW YORK , May 16, 2023 /PRNewswire/ -- Fresh2 Group Limited (Formerly AnPac Bio-Medical Science Co., Ltd., "Fresh2," the "Company" or "we") (NASDAQ: ANPC), a company with operations in the United States and China focused on early cancer screening and detection and entering into the operation of a business-to-business e-commerce food platform focused on the sale of Asian sourced food products, today announced that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2022, with the U.S. Securities and Exchange Commission (the "SEC") on May 16, 2023.

Fresh2 Files Annual Report on Form 20-F for Fiscal Year 2022

NEW YORK , May 16, 2023 /PRNewswire/ -- Fresh2 Group Limited (Formerly AnPac Bio-Medical Science Co., Ltd., "Fresh2," the "Company" or "we") (NASDAQ: ANPC), a company with operations in the United States and China focused on early cancer screening and detection and entering into the operation of a business-to-business e-commerce food platform focused on the sale of Asian sourced food products, announced today its unaudited financial results for the first quarter ended March 31, 2023.

Fresh2 Reports First Quarter of Fiscal Year 2023 Financial Results

NEW YORK , May 16, 2023 /PRNewswire/ -- Fresh2 Group Limited (Formerly AnPac Bio-Medical Science Co., Ltd. ,"Fresh2," the "Company" or "we") (NASDAQ: ANPC), a company with operations in the United States and China focused on early cancer screening and detection and entering into the operation of a business-to-business e-commerce food platform focused on the sale of Asian sourced food products, announced today its annual financial results for the year ended December 31, 2022.

Fresh2 Reports Fiscal Year 2022 Annual Financial Results

NEW YORK , April 6, 2023 /PRNewswire/-- AnPac Bio-Medical Science Co., Ltd. (the "Company") (NASDAQ: ANPC), a company with operations in the United States and China focused on early cancer screening and detection and plans to enter into the operation of a business-to-business e-commerce food platform focused on the sale of Asian sourced food products, today announced the closing of its previously announced registered direct offering pursuant to a securities purchase agreement with certain institutional investors to purchase $3.0 million of its American Depositary Shares ("ADSs"), pre-funded warrants to purchase ADSs and warrants to purchase ADSs.

AnPac Bio-Medical Science Announces Closing of $3.0 Million Registered Direct Offering

NEW YORK , April 3, 2023 /PRNewswire/ -- AnPac Bio-Medical Science Co., Ltd. (the "Company") (NASDAQ: ANPC), a company with operations in the United States and China focused on early cancer screening and detection and entering into the operation of a business-to-business e-commerce food platform focused on the sale of Asian sourced food products, announced that on March 31, 2023, the Company entered into an asset purchase agreement (the "Agreement") with Easy Hundred Inc. ("Easy Hundred"), a U.S.-based e-commerce company in the foodservice industry, through which the Company will acquire certain fixed assets of Easy Hundred and Easy Hundred's intellectual property relating to ez100, 2Supply and 100WAY.

AnPac Bio-Medical Science Enters into Asset Purchase Agreement with Easy Hundred Inc.

New York, NY, March 31, 2023 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (the “Company”) (NASDAQ: ANPC), a company with operations in the United States and China focused on early cancer screening and detection and plans to enter into the operation of a business-to-business e-commerce food platform focused on the sale of Asian sourced food products, today announced that it has entered into a securities purchase agreement with certain institutional investors to purchase $3.0 million of its American Depositary Shares (“ADSs”), pre-funded warrants to purchase ADSs and warrants to purchase ADSs in a registered direct offering.  The Company plans to use the net proceeds from the offering for the advancement of our research and development activities, working capital and general corporate purposes.

AnPac Bio-Medical Science Announces Pricing of $3.0 Million Registered Direct Offering

NEW YORK , March 23, 2023 /PRNewswire/ -- AnPac Bio-Medical Science Co., Ltd. (the "Company") (NASDAQ: ANPC), a company with operations in the United States and China focused on early cancer screening and detection and plans to enter into the operation of a business-to-business e-commerce food platform focused on the sale of Asian sourced food products, announced that on March 22, 2023, the Company has been notified by the Nasdaq Hearings Panel ("Panel") of the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") that the Company's request for continued listing on The Capital Market has been granted, subject to the requirement that the Company demonstrate on or before July 12, 2023, its compliance with the shareholder equity requirement, as outlined in Listing Rule 5550(b)(1) (the "Equity Rule").

AnPac Bio-Medical Science Granted Continued Listing by NASDAQ Hearing Panel, Subject to Meeting the Equity Rule on or before July 12, 2023

NEW YORK , March 7, 2023 /PRNewswire/ – AnPac Bio-Medical Science Co., Ltd. ("AnPac Bio" or the "Company" (Nasdaq: ANPC), a company with operations in the United States and China focused on early cancer screening and detection and plans to enter into the operation of a business-to-business e-commerce food platform focused on the sale of Asian sourced food products, announced today that it has received the first payment in late February 2023 from a Malaysian customer who had signed a US$1.5 million purchase contract for AnPac Bio's Model AP9080 cancer detection devices.

AnPac Bio Announces Receipt of the First Payment from a Malaysia Customer On a Signed US$1.5 Million Cancer Detection Equipment Purchase Contract

NEW YORK , March 6, 2023 /PRNewswire/ -- AnPac Bio-Medical Science Co., Ltd. (Nasdaq: ANPC) ("AnPac Bio," the "Company" or "we"), a company with operations in the United States and China focused on early cancer screening and detection and plans to enter into the operation of a business-to-business e-commerce food platform focused on the sale of Asian sourced food products, announced that on March 2023, the Company has entered into definitive investment agreements with certain accredited investors in a private placement transaction, pursuant to which the investors agreed to subscribe for and purchase, and the Company agreed to issue and sell an aggregate of 16,666,665 newly issued Class A ordinary shares of the Company, at a price of US$0.30 per ordinary share, or US$6.00 per ADS (1:20 ADS-to-share ratio), for an aggregate purchase price of US$5 million.

AnPac Bio-Medical Science Announces US$5 Million Private Placement

NEW YORK , Feb. 22, 2023 /PRNewswire/ -- AnPac Bio-Medical Science Co., Ltd. ("AnPac Bio," the "Company" or "we") (ANPC), a company with operations in the United States and China focused on early cancer screening and detection and plans to enter into the operation of a business-to-business e-commerce food platform focused on the sale of Asian sourced food products, announced up-dated positive results from its first major multi-year and multi-cancer test follow-up study.

AnPac Bio Announces Positive Results from its Multi-Year and Multi-Cancer Test Follow-Up Study

NEW YORK , Feb. 15, 2023 /PRNewswire/ -- AnPac Bio-Medical Science Co., Ltd. (the "Company") (NASDAQ: ANPC), a company with operations in the United States and China focused on early cancer screening and detection and plans to enter into the operation of a business-to-business e-commerce food platform focused on the sale of Asian sourced food products, announced the closing of the acquisition of GISN (HK) LIMITED ("GISN"), a technical solution and outsourcing consulting services provider focused on the digital, internet and Web 3 business transformation for start-ups and traditional enterprises.

AnPac Bio-Medical Science Acquires GISN (HK) LIMITED, a Technical Solution and Outsourcing Consulting Services Provider

NEW YORK , Feb. 13, 2023 /PRNewswire/ -- AnPac Bio-Medical Science Co., Ltd. (the "Company") (NASDAQ: ANPC), a company with operations in the United States and China announced that on February 12, 2023, the Company, through its subsidiary Foodbase Group Inc., entered into a definitive equity purchase agreement to acquire a group of affiliated companies, SLV Windfall Group LLC, Windfall SLV Development LLC and SLV Windfall Management, LLC, which are engaged in developing, marketing and selling real estate in Savannah Lakes Village, a planned community located in McCormick County, South Carolina.

AnPac Bio-Medical Science Enters into Definitive Agreement to Make Another Acquisition to Significantly Expand Scope of Business in the U.S.

Transaction expected to fuel the Company's growth in the U.S. food market NEW YORK , Feb. 9, 2023 /PRNewswire/ -- AnPac Bio-Medical Science Co., Ltd. (the "Company") (NASDAQ: ANPC), a company with operations in the United States and China focused on early cancer screening and detection and plans to enter into the operation of  a business-to-business e-commerce food platform focused on the sale of Asian sourced food products, announced that on February 7, 2023, the Company through a subsidiary, Fresh2 Technology Inc., has entered into a definitive stock purchase agreement (the "SPA") to acquire Fresh2 Ecommerce Inc ("Fresh2 Ecommerce"), a business-to-business e-commerce platform focused on  connecting Asian food suppliers and supermarkets in the U.S. Fresh2 Ecommerce provides an online direct selling platform for food suppliers such as food companies, manufacturers, agents, importers, and wholesalers to supermarkets.

AnPac Bio-Medical Science Enters into Definitive Agreement to Acquire Fresh2 Ecommerce Inc, a B2B Asian Food E-commerce Platform

New York, NY, Jan. 25, 2023 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (the “Company”) (Nasdaq: ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection and a business-to-business food e-commerce company, announced that in December 2022 and January 2023, the Company signed definitive investment agreements with several third party investors. The investors agreed to purchase 29,714,279 newly issued Class A ordinary shares (1,485,714 American Depositary Shares or “ADSs”) of the Company at a price of US$0.175 per ordinary share or US$3.50 per ADS (1:20 ADS-to-share ratio), for a total purchase price of US$5.2 million. The closing is expected to take place within 30 days after signing. Concurrently, for each Class A ordinary share purchased, the investors will receive two warrants with each warrant to purchase one Class A ordinary share at an exercise price of US$0.21 per ordinary share (2,971,428 ADS an at exercise price of US$4.20 per ADS). The warrants will be exercisable within 2 years from the date of issuance.

AnPac Bio-Medical Science Announces Signing of US$5.2 Million of Definitive Investment Agreements

New York, NY, Jan. 20, 2023 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (the “Company”) (Nasdaq: ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection announced that, on January 13, 2023, it received a Staff determination letter (the “Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company of the Staff's determination to delist the Company's securities from The Nasdaq Capital Market due to the Company's failure to comply with the minimum $2.5 million stockholders' equity requirement for continued listing on The Nasdaq Capital Market (the “Equity Rule”), unless the Company timely requests a hearing before a Nasdaq Hearings Panel (the “Panel”). Accordingly, the Company intends to timely request a hearing. The hearing request will automatically stay any delisting or suspension action relating to the Company's American Depositary Shares through the hearing and the expiration of any additional extension period granted by the Panel following the hearing.

AnPac Bio-Medical Sciences Announces Receipt of Staff Delisting Determination from Nasdaq; Intends to Request A Hearing

PHILADELPHIA, Dec. 19, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, announced today its unaudited financial results for the six months ended June 30, 2022.

AnPac Bio Reports 48.8% Decrease in Net Loss in First Half of 2022

PHILADELPHIA, Dec. 05, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (Nasdaq: ANPC) (“AnPac Bio” or the “Company”), a biotechnology company with operations in the United States and China focused on early cancer screening and detection, today announced that the Company has formed a wholly-owned subsidiary Fresh2 Technology Inc in the State of Delaware on October 4, 2022 in order to establish the company's new product line of business-to-business food trade and delivery platform for local restaurants and supermarkets, a combination of the China's food distribution strategies and North America's growing Asian food market.

AnPac Announces Strategic Initiative to Establish A Wholly-Owned Subsidiary for US Food Market

PHILADELPHIA, Dec. 05, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (Nasdaq: ANPC) (“AnPac Bio” or the “Company”), a biotechnology company with operations in the United States and China focused on early cancer screening and detection, today announced that the Company has reached a mutual understanding with nine investors. The investors will subscribe for and purchase from the Company through a private placement a total of 28,571,428 newly issued Class A ordinary shares of the Company at a price of US$3.5 per ADS, US$0.175 per ordinary share (1:20 ADS-to-share ratio), for a total purchase price of $5 million. The transaction is subject to customary closing conditions and the closing is expected to take place within 3 months after this announcement.

AnPac Announces the Plan of US$5,000,000 Private Placement

PHILADELPHIA, Nov. 30, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (Nasdaq: ANPC) (“AnPac Bio” or the “Company”), a biotechnology company with operations in the United States and China focused on early cancer screening and detection, today announced that the company has been notified by the Office of the General Counsel of The Nasdaq Stock Market LLC that the Company has regained compliance with the minimum $1 per share bid price requirement of Listed Securities required for continued listing as set forth in Listing Rule 5450(a)(1). The Company will remain under the Mandatory Panel Monitor until June 9, 2023, imposed by a previous Hearings Panel's decision on June 9, 2022.

AnPac Announces Regaining Compliance with Nasdaq Listing Requirement

PHILADELPHIA, Nov. 10, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (Nasdaq: ANPC) (“AnPac Bio” or the “Company”), a biotechnology company with operations in the United States and China focused on early cancer screening and detection, today announced the resignation of Yuyang Cui as (i) the Co-Chair of the board of directors (the “Board”), and (ii) the Co-Chief Executive Officer, effective from November 7, 2022, and the resignation of Jiawen Kang from the position of (i) a director of the Board, (ii) a member of the audit committee, and (iii) a member of the nominating and corporate governance committee, effective from November 4, 2022.

AnPac Bio Announces Changes to the Board of Directors

PHILADELPHIA, Nov. 04, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection, announced that on October 31, 2022, the Company has been notified by the Nasdaq Hearings Panel of the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) that the Company's request for continued listing on The Capital Market has been granted, subject to the following:

AnPac Bio Granted Continued Listing by NASDAQ Hearing Panel, Subject to Meeting $1 Bid Price Compliance Rule On or Before Nov. 23, 2022

Adamis Pharmaceuticals

Borqs Technologies

Clever Leaves Holdings

Cosmos Holdings

Corbus Pharmaceuticals Holdings

Altamira Therapeutics Ltd

Matinas BioPharma Hlds

Nutex Health Inc

Oblong

Penny stocks to watch under $1 right now. The post 10 Top Penny Stocks To Buy For Uner $1 Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

10 Top Penny Stocks To Buy For Uner $1 Right Now

Penny stocks to watch under $1 right now. The post Good Penny Stocks To Buy Now?

Good Penny Stocks To Buy Now? 7 Under $1 To Watch This Week

PHILADELPHIA, Oct. 18, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (Nasdaq: ANPC) (“AnPac Bio” or the “Company”), a biotechnology company with operations in the United States and China focused on early cancer screening and detection, today announced that it plans to change the ratio of the Company's American Depositary Shares (“ADSs”) to its Class A ordinary shares from one (1) ADS representing one (1) Class A ordinary share to one (1) ADS representing twenty (20) Class A ordinary shares. The change in the ADS ratio is expected to take place on November 4, 2022 (US Eastern time).

News for AnPac Bio-Medical Science Co Stock (ANPC)